If you have been reading about Phase 3 trial and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
=== Cancer === Higher vitamin C intake appears to reduce the risk for lung cancer. There is no evidence that vitamin C supplementation reduces the risk of prostate cancer, colorectal cancer or breast cancer.
Open-angle glaucoma usually presents with no symptoms early in the course of the disease, but it may gradually progress to involve difficulties with vision. It usually involves deficits in the peripheral vision followed by central vision loss as the disease progresses, but less commonly it may present as central vision loss or patchy areas of vision loss. On an eye examination, optic nerve changes are seen indicating damage to the optic nerve head (increased cup-to-disc ratio on fundoscopic examination). Acute angle-closure glaucoma, a medical emergency due to the risk of impending permanent vision loss, is characterized by sudden ocular pain, seeing halos around lights, red eye, very high intraocular pressure, nausea and vomiting, and suddenly decreased vision. Acute angle-closure glaucoma may further present with corneal edema, engorged conjunctival vessels, and a fixed and dilated pupil on examination. Opaque specks may occur in the lens in glaucoma, known as glaukomflecken. The word is German, meaning "glaucoma-specks".
== Epidemiology == Necrobiosis Lipoidica is known to have a strong correlation with diabetes mellitus. It occurs after the diagnosis of diabetes mellitus in 64% of cases. However, there is no conclusive association between the two. NL may present itself in a completely healthy individual. It is also found in people with other metabolic diseases, thyroid disorders, and inflammatory diseases. It occurs predominantly in females, in a 3:1 ratio compared to males. Onset of NL typically occurs at ages 30-50 but is not exclusively linked to this range. A few studies have found that ulceration is most common in male patients with diabetes mellitus.
=== Natural occurrence === Earth has retained all of the noble gases that were present at its formation except helium. Krypton's concentration in the atmosphere is about 1 ppm. It can be extracted from liquid air by fractional distillation. The amount of krypton in space is uncertain, because measurement is derived from meteoric activity and solar winds. The first measurements suggest an abundance of krypton in space.
Sources: en.wikipedia.org
{\displaystyle Q={\begin{pmatrix}{-(a\pi _{C}+b\pi _{G}+c\pi _{T})}&a\pi _{C}&b\pi _{G}&c\pi _{T}\\a\pi _{A}&{-(a\pi _{A}+d\pi _{G}+e\pi _{T})}&d\pi _{G}&e\pi _{T}\\b\pi _{A}&d\pi _{C}&{-(b\pi _{A}+d\pi _{C}+f\pi _{T})}&f\pi _{T}\\c\pi _{A}&e\pi _{C}&f\pi _{G}&{-(c\pi _{A}+e\pi _{C}+f\pi _{G})}\end{pmatrix}}}
=== Protein–protein interactions === (Yeast) two-hybrid system Protein-fragment complementation assay Co-immunoprecipitation Affinity purification and mass spectrometry Proximity ligation assay Proximity labeling
=== Translation === Ninety of the Bloomberg tablets have been translated. This is the highest number of translated artefacts from any comparable archaeological site in London, surpassing the previous record of 19. Alongside the 90 translated tablets are another 91 stylus tablets, all which have been inscribed but are considered illegible. The 90 translated tablets have been grouped according to the content translated within, 43 of these tablets contained general correspondence, 25 of them were financial or legal documentation, 8 tablets were book keeping accounts showing what people owed and the remaining 14 are miscellaneous. The tablets were translated by Dr Roger Tomlin, an expert in Roman cursive, the writing style in which the tablets were written. Tablets vary in content, including the oldest financial document from London (dating to 8 January 57 AD), about 3 to 4 years before the city was destroyed by Boudica. It also documents how the Roman government responded with their military and how soon the city recovered thereafter. Legal documents include a judge calling a pretrial hearing, and educational material. One tablet shows the alphabet written out, indicating the presence of perhaps the first school in Britain. Additionally, among the tablets there are over 100 names of people of all different professions and social classes who lived in London at the time, such as slaves, merchants, soldiers, and politicians. One prominent figure that is named is Julius Classicus, who was a commander in the Roman auxiliaries.
=== IRAP catalytic site inhibitors === Peptidomimetics The first reported IRAP inhibitors were designed as angiotensin IV (AngIV) analogs. In 2006, Axén et al published a macrocyclized version of an AngIV derivative (Compound 1) which confers metabolic stability together with high affinity for IRAP (Ki = 25.8 nM). Under a similar scope Lukaszuk et al produced compound AL-11, which was able to inhibit IRAP (Ki = 27.5 nM) and displayed around 200-fold selectivity over APN. Further structural modifications on the AngIV-based inhibitors from Anderson et al led to optimized macrocycle HA08 (available crystal structure within IRAP, Figure 2) with excellent IRAP potency (Ki = 3.3 nM) and selectivity over APN, but poor metabolic stability.
=== Strain-promoted alkyne-nitrone cycloaddition (SPANC) === Diaryl-strained-cyclooctynes including dibenzylcyclooctyne (DIBO) have also been used to react with 1,3-nitrones in strain-promoted alkyne-nitrone cycloadditions (SPANC) to yield N-alkylated isoxazolines.
Sources: en.wikipedia.org
Apart from the failed Third Period policy in the early 1930s, Marxist–Leninists played an important role in anti-fascist resistance movements, with the Soviet Union contributing to the Allied victory in World War II. In accordance with the three-power Yalta Agreement (4–11 February 1945), the Soviet Union purged native fascist collaborators and these in collaboration with the Axis Powers from the Eastern European countries occupied by the Axis Powers and installed native Marxist–Leninist governments.
=== Neurotransmission === Inhibitory neurons in the central nervous system play a homeostatic role in the balance of neuronal activity between excitation and inhibition. Inhibitory neurons using GABA, make compensating changes in the neuronal networks preventing runaway levels of excitation. An imbalance between excitation and inhibition is seen to be implicated in a number of neuropsychiatric disorders.
In 2006, Valerie O'Neil, a Starbucks spokeswoman, said that the logo is an image of a "twin-tailed mermaid, or siren as she's known in Greek mythology". The logo has been significantly streamlined over the years. In the first version, the Starbucks siren was topless and had a fully visible double fish tail. The image was said by Starbucks to be based on a 16th-century "Norse" woodcut, although other scholars note that it is apparently based on a 15th-century woodcut in Juan Eduardo Cirlot's Dictionary of Symbols. Some scholars have identified the image as Melusine. The connection to Melusine has been questioned; Melusine was not linked to heraldic images of two-tailed mermaids until the late 19th century, making it possibly a late misidentification. In the second logo, which was used from 1987 to 1992, the siren's breasts were covered by her flowing hair, but her navel was still visible. The fish tail was cropped slightly, and the primary color was changed from brown to green, a nod to the Alma Mater of the three founders, the University of San Francisco. In the third version, used between 1992 and 2011, her navel and breasts are not visible at all, and only vestiges remain of the fish tails. The original "woodcut" logo has been moved to the Starbucks's Headquarters in Seattle. At the beginning of September 2006, and then again in early 2008, Starbucks temporarily reintroduced its original brown logo on paper hot-drink cups. Starbucks has stated that this was done to show the company's heritage from the Pacific Northwest and to celebrate 35 years of business.
=== Neurological === CCK is found extensively throughout the central nervous system, with high concentrations found in the limbic system. CCK is synthesized as a 115 amino acid preprohormone, that is then converted into multiple isoforms. The predominant form of CCK in the central nervous system is the sulfated octapeptide, CCK-8S.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.